Mistletoe to Treat Cancer - Quick Reference Sheet
evipedia.ai
← Back

Mistletoe to Treat Cancer

Created on 09/12/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Injected mistletoe extract, used in European cancer care for a century, shows its strongest evidence for how people feel: better wellbeing, less exhaustion, better tolerance of chemotherapy. Longer-life claims hold only in studies where everyone knew who was treated. Skin reactions at the injection site are near-universal, fever common, severe allergy rare. The danger is displacing treatment that works. (Full Review)

Protocol

Standard route and frequency
Subcutaneous, 2-3× weekly
Injection into the abdomen, thigh or upper arm, given continuously rather than in short courses.
Dose escalation series
0.01 mg → 10 mg
Preparations are supplied as graded ampoule series; trials escalated over weeks.
Best time of day
Morning
Aligns the induced warmth reaction with the daytime rise in body temperature; evening dosing is avoided.
Time to effect
Symptomatic change
4-12 weeks
Changes in fatigue, appetite and sleep were assessed at 4-12 weeks in trials.
Survival endpoints
Months
Survival endpoints require months.
Local skin reaction
Within days
Confirms only that dosing is adequate.

Benefits

Contraindications
  • Known hypersensitivity to any Viscum album preparation, or prior anaphylaxis to mistletoe or other plant lectins
  • Primary or secondary brain tumours with raised pressure inside the skull, or symptomatic swelling around the tumour
  • Leukaemia and malignant lymphoma
  • Solid organ transplant recipients on maintenance immunosuppression
  • Acute febrile illness with temperature above 38 °C, or suspected active infection, until resolved
  • Untreated hyperthyroidism (overactive thyroid) with resting heart rate above 100 beats per minute
  • Poorly controlled autoimmune disease currently requiring systemic immunosuppression, or any active flare
  • Pregnancy and lactation
  • Eastern Cooperative Oncology Group performance status 4 (completely bedbound)
    •
Key Interactions
  • Immunosuppressants (ciclosporin, tacrolimus, azathioprine, mycophenolate)
  • Systemic corticosteroids (prednisolone, dexamethasone)
  • Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab, atezolizumab)
  • Warfarin
  • Cytotoxic chemotherapy (platinum agents, gemcitabine, taxanes)
  • Over-the-counter antipyretics and analgesics (paracetamol, ibuprofen, aspirin)
  • Over-the-counter antihistamines (cetirizine, loratadine, diphenhydramine)
  • Over-the-counter blood-pressure-lowering herbal products (hawthorn, garlic, hibiscus)
  • Immunostimulant supplements (echinacea, beta-glucans, reishi and turkey tail mushroom extracts)
  • Thermotherapy, fever therapy and hyperthermia
  • Positron emission tomography scans
    •

Risk & Side Effects

  • High: Local injection-site reactions; flu-like symptoms, fever, chills and fatigue
    •
  • Medium: Allergic and hypersensitivity reactions, including anaphylaxis; grade 3 or higher toxicity at high intravenous doses
    •
  • Low: Reversible liver enzyme elevation at high lectin doses; procedure-related pain and fever with intrapleural instillation; displacement of effective conventional treatment
    •
  • Speculative: Tumour growth stimulation at low doses; amplified immune-related adverse events with checkpoint inhibitors
    •

Monitoring

Marker Target Why
Body temperature 36.5-37.4 °C at rest; post-injection rise staying below 38 °C The primary dose-finding signal and the hold threshold
Local reaction diameter 0.5-5 cm redness resolving within 72 hours The other half of dose titration; defines adequate exposure
Full blood count with differential Lymphocytes 20-40% of white cells; eosinophils below 5% Tracks the intended immune shift and detects marrow effects of concurrent chemotherapy
C-reactive protein Below 1.0 mg/L at baseline; transient rises to 3-10 mg/L after escalation are expected Distinguishes treatment-driven inflammation from infection
Liver enzymes: ALT, AST, GGT ALT and AST below 25 U/L in women and 30 U/L in men; GGT below 25 U/L High lectin exposure has produced reversible enzyme rises
Tumour markers: CA 19-9, CEA, CA 125 No established universal target; track direction of change against the individual's own pre-treatment value Cheapest available signal of disease trajectory
Albumin 4.0-5.0 g/dL Nutritional and prognostic anchor in advanced disease
Thyroid-stimulating hormone 0.5-2.0 mIU/L Untreated overactive thyroid is a listed contraindication
Body weight Stable or rising; unintentional loss above 5% in 3 months is a red flag Weight trend paralleled quality-of-life change in the pancreatic cancer trial

Cadence: Temperature and local reaction diameter after every injection during escalation, then weekly at a stable dose; blood count, C-reactive protein and liver enzymes at 4 weeks, then every 3 months; thyroid-stimulating hormone and albumin every 3-6 months; tumour markers every 6-12 weeks; body weight weekly.

Qualitative Assessment

  • Fatigue: capacity for a normal day's activity without enforced rest
  • Appetite and enjoyment of food
  • Sleep quality and continuity, particularly whether injection-related fever is disturbing nights
  • Pain burden and analgesic requirement
  • Sense of warmth and wellbeing in the hours after injection
  • Emotional resilience and the ability to engage with treatment decisions
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.